Published in February 2013, study to determine the effectiveness of naltrexone in low doses for fibromyalgia has again displayed positive results as a good treatment option for this condition. Low Dose Naltrexone showed significant reduction in baseline pain, improvement with general quality of life and also mood improvement.
Abstract of study is below.
Low-dose naltrexone for the treatment of fibromyalgia: Findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
Arthritis Rheum. 2013 Feb;65(2):529-38. doi: 10.1002/art.37734.
Younger J, Noor N, McCue R, Mackey S.
Source
Stanford University School of Medicine, Palo Alto, California. jarred.younger@stanford.edu.
Abstract
OBJECTIVE:
To determine whether low dosages (4.5 mg/day) of naltrexone reduce fibromyalgia severity as compared with the nonspecific effects of placebo. In this replication and extension study of a previous clinical trial, we tested the impact of low-dose naltrexone on daily self-reported pain. Secondary outcomes included general satisfaction with life, positive mood, sleep quality, and fatigue.
METHODS:
Thirty-one women with fibromyalgia participated in the randomized, double-blind, placebo-controlled, counterbalanced, crossover study. During the active drug phase, participants received 4.5 mg of oral naltrexone daily. An intensive longitudinal design was used to measure daily levels of pain.
RESULTS:
When contrasting the condition end points, we observed a significantly greater reduction of baseline pain in those taking low-dose naltrexone than in those taking placebo (28.8% reduction versus 18.0% reduction; P = 0.016). Low-dose naltrexone was also associated with improved general satisfaction with life (P = 0.045) and with improved mood (P = 0.039), but not improved fatigue or sleep. Thirty-two percent of participants met the criteria for response (defined as a significant reduction in pain plus a significant reduction in either fatigue or sleep problems) during low-dose naltrexone therapy, as contrasted with an 11% response rate during placebo therapy (P = 0.05). Low-dose naltrexone was rated equally tolerable as placebo, and no serious side effects were reported.
CONCLUSION:
The preliminary evidence continues to show that low-dose naltrexone has a specific and clinically beneficial impact on fibromyalgia pain. The medication is widely available, inexpensive, safe, and well-tolerated. Parallel-group randomized controlled trials are needed to fully determine the efficacy of the medication.
Copyright © 2013 by the American College of Rheumatology.
- PMID:
- 23359310
- [PubMed - in process]
The following toggler user interface control may not be accessible. Tab to the next button to revert the control to an accessible version.
Destroy user interface control
Low-dose naltrexone for the treatment of fib... [Arthritis Rheum. 2013] - PubMed - NCBI:
'via Blog this'
No comments:
Post a Comment